Scarica l'app Stockscreener
11.27
0.13%
0.010
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VERV Giù?
Forum
Previsione
Precedente Chiudi:
$11.26
Aprire:
$11.225
Volume 24 ore:
341.22K
Relative Volume:
0.07
Capitalizzazione di mercato:
$569.18M
Reddito:
$20.65M
Utile/perdita netta:
$-192.65M
Rapporto P/E:
-4.3494
EPS:
-2.59
Flusso di cassa netto:
$-134.39M
1 W Prestazione:
+1.90%
1M Prestazione:
+162.70%
6M Prestazione:
+87.21%
1 anno Prestazione:
+136.76%
Intervallo 1D:
$11.22
$11.28
Intervallo di 1 settimana:
$11.04
$11.28
Portata 52W:
$2.8647
$11.40
Verve Therapeutics Inc Stock (VERV) Company Profile
Nome
Verve Therapeutics Inc
Settore
Industria
Telefono
(978) 501-3026
Indirizzo
201 BROOKLINE AVENUE, BOSTON
Confronta VERV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
11.27 | 569.18M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.90 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
528.65 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
562.75 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.38 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-12-15 | Iniziato | Goldman | Sell |
| 2022-10-06 | Iniziato | Credit Suisse | Neutral |
| 2022-08-25 | Aggiornamento | Stifel | Hold → Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-09-24 | Iniziato | Stifel | Hold |
| 2021-07-12 | Iniziato | Guggenheim | Buy |
| 2021-07-12 | Iniziato | JP Morgan | Neutral |
| 2021-07-12 | Iniziato | Jefferies | Buy |
| 2021-07-12 | Iniziato | William Blair | Outperform |
Mostra tutto
Verve Therapeutics Inc Borsa (VERV) Ultime notizie
VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc.VERV - Business Wire
Verve Therapeutics Stock Price, Quotes and Forecasts - Benzinga
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - MSN
Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1B Deal - GuruFocus
Lilly to acquire Verve Therapeutics for $1.3 billion - C&EN
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Verve Therapeutics’ SWOT analysis: gene-editing stock shows promise amid challenges - Investing.com
Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition - TipRanks
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - MSN
Verve Therapeutics downgraded to Hold from Buy at Canaccord - Yahoo Finance
Eli Lilly nears $1.3B deal for Verve Therapeuticsreport - MSN
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView
Beyond Obesity: Eli Lilly’s Genetic Medicine Bet On Verve Therapeutics - Forbes
This Verve Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday - Benzinga
HC Wainwright Downgrades Verve Therapeutics (VERV) Rating to Neutral | VERV Stock News - GuruFocus
Jefferies Downgrades Verve Therapeutics (VERV), Lowers Price Tar - GuruFocus
Verve Therapeutics (VERV): Downgrade and Updated Price Target | - GuruFocus
Lilly to acquire Verve Therapeutics to advance gene editing treatments - World Pharmaceutical Frontiers
Lock In The 81.5% Run: Initiating Verve With A Sell (NASDAQ:VERV) - Seeking Alpha
Canaccord Genuity Downgrades Verve Therapeutics to Hold From Buy - marketscreener.com
HC Wainwright Downgrades Verve Therapeutics to Neutral From Buy, $25 Price Target - MarketScreener
Verve Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Hold Rating on Verve Therapeutics Acquisition by Eli Lilly: Fair Valuation with Low Competing Bid Potential - TipRanks
Verve Therapeutics (VERV) Downgraded After Acquisition Agreement | VERV Stock News - GuruFocus
Lilly Eyes Future of One-Time Cardiovascular Health with $1.3B Verve Therapeutics Acquisition - geneonline.com
Verve Therapeutics downgraded to Hold from Buy at Jefferies - TipRanks
Jefferies cuts Verve Therapeutics stock rating on Lilly acquisition news - Investing.com
M&A News: Verve Therapeutics Stock (VERV) Rallies 75% on News of Potential Acquisition by Eli Lilly - The Globe and Mail
Eli Lilly to acquire for Verve Therapeutics for up to $1.3B - MSN
Verve Therapeutics (VERV) Downgraded Following Acquisition Annou - GuruFocus
Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High? - MSN
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover - MSN
Eli Lilly lands “bargain” deal to acquire Verve Therapeutics for $1.3bn - MSN
Why Verve Therapeutics Stock Is Skyrocketing Today - MSN
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say - The Mighty 790 KFGO
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say By Reuters - Investing.com
Lilly to acquire Verve Therapeutics for up to $1.3 billion By Investing.com - Investing.com South Africa
Verve Therapeutics (VERV) Downgraded by William Blair | VERV Sto - GuruFocus
Verve Therapeutics (VERV) Downgraded by Canaccord Genuity | VERV Stock News - GuruFocus
In a $1.3B deal, Lilly buys gene editor Verve - BioWorld MedTech
Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve - insights.citeline.com
Wilson Sonsini Advises Verve Therapeutics on IP Matters Related to Merger with Lilly - Wilson Sonsini
Stocks to Watch Recap: T-Mobile, Eli Lilly, Verve Therapeutics, First Solar - WSJ
These Stocks Moved the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More - Barron's
Verve Therapeutics downgraded to Market Perform from Outperform at LifeSci - TipRanks
Eli Lilly strikes $1.3 billion deal to buy gene-editing biotech Verve Therapeutics, companies say - MSN
Hold Rating on Verve Therapeutics Amid Acquisition and Development Milestones - TipRanks
Verve Therapeutics (VERV) Receives Downgrade Following Acquisiti - GuruFocus
Eli Lilly Gets Into The Gene-Editing Space With $1 Billion Takeout - Investor's Business Daily
Verve: Eli Lilly Acquisition Based On One-Time GalNAc PCSK9 Gene Editing Program - Seeking Alpha
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - MSN
Verve Therapeutics Inc Azioni (VERV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Verve Therapeutics Inc Azioni (VERV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nickerson Joan | Chief Administrative Officer |
Apr 02 '25 |
Sale |
4.15 |
2,777 |
11,525 |
17,420 |
| Ashe Andrew D. | See Remarks |
Apr 02 '25 |
Sale |
4.15 |
2,681 |
11,126 |
348,828 |
| Politi Jason | Chief Technical Ops. Off. |
Apr 02 '25 |
Sale |
4.15 |
3,235 |
13,425 |
14,226 |
| Dorval Allison | Chief Financial Officer |
Apr 02 '25 |
Sale |
4.15 |
3,350 |
13,903 |
13,280 |
| Lister Troy | Chief Scientific Officer |
Apr 02 '25 |
Sale |
4.15 |
2,189 |
9,084 |
6,952 |
| Dorval Allison | Chief Financial Officer |
Dec 02 '24 |
Sale |
5.64 |
555 |
3,130 |
5,380 |
| Kathiresan Sekar | Chief Executive Officer |
Jun 28 '24 |
Option Exercise |
2.87 |
30,000 |
86,100 |
351,128 |
1.37%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):